Synthesis and evaluation of mesoporous carbon/lipid bilayer nanocomposites for improved oral delivery of the poorly water-soluble drug, nimodipine

Pharmaceutical Research

Volumn 32, Issue 7, 2015, Pages 2372-2383

  Zhang, Yanzhuo ^a   Zhao, Qinfu ^b   Zhu, Wufu ^c   Zhang, Lihua ^a   Han, Jin ^a   Lin, Qisi ^a   Ai, Fengwei ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c JIANGXI SCIENCE AND TECHNOLOGY NORMAL UNIVERSITY   (China)

Author keywords

drug absorption; lipid bilayer; mesoporous carbon; nano drug delivery system; sustained release

Indexed keywords

MESOPOROUS CARBON LIPID BILAYER NANOCOMPOSITE; NANOCARRIER; NANOCOMPOSITE; NANOSPHERE; NIMODIPINE; UNCLASSIFIED DRUG; CARBON; DRUG CARRIER; LIPID BILAYER; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID BILAYER; MAXIMUM PLASMA CONCENTRATION; MTT ASSAY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SURFACE AREA; SUSTAINED DRUG RELEASE; SYNTHESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; BIOAVAILABILITY; BIOLOGICAL MODEL; CACO 2 CELL LINE; CHEMISTRY; HT 29 CELL LINE; ORAL DRUG ADMINISTRATION; POROSITY; SOLUBILITY; SURFACE PROPERTY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBON; DRUG CARRIERS; DRUG LIBERATION; FREEZE DRYING; HT29 CELLS; HUMANS; LIPID BILAYERS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; NANOCOMPOSITES; NIMODIPINE; POROSITY; SOLUBILITY; SURFACE PROPERTIES; WATER; X-RAY DIFFRACTION;

EID: 84930177288     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1630-5     Document Type: Article

References (44)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64:4-17.
2. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2001;420(1):1-10.
3. Nkansah P, Antipas A, Lu Y, Varma M, Rotter C, Rago B, et al. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs. J Control Release. 2013;169(1-2):150-61.
4. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-75.
5. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231-48.
6. Hill A, Geissler S, Weigandt M, Mader K. Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics. J Control Release. 2012;158(3):403-12.
7. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011;16(7-8):354-60.
8. Hamoudi MC, Bourasset F, Domergue-Dupont V, Gueutin C, Nicolas V, Fattal E, et al. Formulations based on alpha cyclodextrin and soybean oil: an approach to modulate the oral release of lipophilic drugs. J Control Release. 2012;161(3):861-7.
9. Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-96.
10. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56(9):1273-89.
11. Nguyen TH, Hanley T, Porter CJ, Boyd BJ. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. J Control Release. 2011;153(2):180-6.
12. Zhang Y, Wang J, Bai X, Jiang T, Zhang Q, Wang S. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol Pharm. 2012;9(3):505-13.
13. Chirra HD, Desai TA. Emerging microtechnologies for the development of oral drug delivery devices. Adv Drug Deliv Rev. 2012;64(14):1569-78.
14. Tan S, Li X, Guo Y, Zhang Z. Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale. 2013;5:860-72.
15. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-22.
16. Su X, Fricke J, Kavanagh DJ, Irvine DJ. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol Pharm. 2011;8(3):774-87.
17. Mendes LP, Gaeti MP, de Ávila PH, de Sousa VM, Dos Santos RB, de Ávila Marcelino RI, et al. Multicompartimental nanoparticles for co-encapsulation and multimodal drug delivery to tumor cells and neovasculature. Pharm Res. 2014;31(5):1106-19.
18. Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011;44(10):1094-104.
19. Wang C, Wang Y, Fan M, Luo F, Qian Z. Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. Int J Pharm. 2011;414(1-2):251-9.
20. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557-70.
21. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomed Nanotech Biol Med. 2009;5(4):410-8.
22. Wani A, Muthuswamy E, Savithra GHL, Mao G, Brock S, Oupický D. Surface functionalization of mesoporous silica nanoparticles controls loading and release behavior of mitoxantrone. Pharm Res. 2012;29(9):2407-18.
23. Zhang Y, Wang H, Li C, Sun B, Wang Y, Wang S, et al. A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib. Pharm Res. 2014;31(4):1059-70.
24. Liang C, Li Z, Dai S. Mesoporous carbon materials: synthesis and modification. Angew Chem. 2008;47(20):3696-717.
25. 1 alloy nanoparticles in large pore size mesocellular carbon foam for improved methanol-tolerant oxygen reduction reaction. Carbon. 2011;49(4):1108-17.
26. Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1989;37:669-99.
27. Chalikwar SS, Belgamwar VS, Talele VR, Surana SJ, Patil MU. Formulation and evaluation of nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surface B. 2012;97(1):109-16.
28. Sun Y, Rui Y, Wenliang Z, Tang X. Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. Int J Pharm. 2008;359(1-2):144-9.
29. Fuhr U, Maier-Bruggemann A, Blume H, Muck W, Unger S, Kuhlmann J, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998;36(3):126-32.
30. Li M, Xue J. Ordered mesoporous carbon nanoparticles with well-controlled morphologies from sphere to rod via a soft-template route. J Colloid Interface Sci. 2012;377(1):169-75.
31. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum. 1965;4:117-212.
32. Fang Y, Gu D, Zou Y, Wu Z, Li F, Che R, et al. A low-concentration hydrothermal synthesis of biocompatible ordered mesoporous carbon nanospheres with tunable and uniform size. Angew Chem Int Ed. 2010;49(43):7987-91.
33. Yang P, Quan Z, Lu L, Huang S, Lin J. Luminescence functionalization of mesoporous silica with different morphologies and applications as drug delivery systems. Biomaterials. 2008;29(6):692-702.
34. Van Speybroeck M, Mellaerts R, Mols R, Thi TD, Martens JA, Van Humbeeck J, et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci. 2010;41(5):623-30.
35. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the Biopharmaceutics classification system. Int J Pharm. 2006;321(1-2):1-11.
36. May S, Jensen B, Weiler C, Wolkenhauer M, Schneider M, Lehr CM. Dissolution testing of powders for inhalation: influence of particle deposition and modeling of dissolution profiles. Pharm Res. 2014;31(11):3211-24.
37. Hong Y, Chen X, Jing X, Fan H, Guo B, Gu Z, et al. Preparation, bioactivity, and drug release of hierarchical nanoporous bioactive glass ultrathin fibers. Adv Mater. 2010;22(6):754-8.
38. Kapoor S, Hegde R, Bhattacharyya AJ. Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release. J Control Release. 2009;140(1):34-9.
39. Cauda V, Muhlstein L, Onida B, Bein T. Tuning drug uptake and release rates through different morphologies and pore diameters of confined mesoporous silica. Microporous Mesoporous Mater. 2009;118(1-3):435-43.
40. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Brit J Clin Pharmacol. 1998;46(2):101-10.
41. Peters WH, Kock L, Nagengast FM, Kremers PG. Biotransformation enzymes in human intestine: critical low levels in the colon? Gut. 1991;32(4):408-12.
42. McKinnon RA, McManus ME. Localization of cytochromes P450 in human tissues: implications for chemical toxicity. Pathol (Phila). 1996;28(2):148-55.
43. Davis SS. Formulation strategies for absorption windows. Drug Discov Today. 2005;10(4):249-57.
44. Des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1-27.